Sacubitril/Valsartan: Neprilysin Inhibition 5 Years Later Sacubitril/Valsartan: Neprilysin Inhibition 5 Years Later
In 2014, the PARADIGM-HF trial determined that sacubitril/valsartan improved outcomes compared to enalapril in patients with chronic HFrEF. What have we learned about neprilysin inhibition since?JACC: Heart Failure (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 4, 2020 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
enalapril and hydrochlorothiazide (Vaseretic)
Title: enalapril and hydrochlorothiazide (Vaseretic)Category: MedicationsCreated: 4/3/1999 12:00:00 AMLast Editorial Review: 10/23/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - October 23, 2019 Category: Cardiology Source Type: news
Sacubitril-Valsartan Does Not Impact Aortic Stiffness in HFrEF
WEDNESDAY, Sept. 4, 2019 -- For patients with heart failure and reduced ejection fraction (HFrEF), sacubitril-valsartan does not impact aortic stiffness versus enalapril but is associated with improvements in cardiac structure and function,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 4, 2019 Category: Pharmaceuticals Source Type: news
PIONEER-HF: In ADHF, Early ARNI Seems Key to Best Clinical Gains PIONEER-HF: In ADHF, Early ARNI Seems Key to Best Clinical Gains
Failure to start therapy in hospital is a ' lost opportunity, ' say researchers from evidence that such early sacubitril/valsartan bested enalapril more in the earliest weeks after discharge than later.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 29, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news
enalapril (Vasotec, Epaned)
Title: enalapril (Vasotec, Epaned)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 3/18/2019 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - March 18, 2019 Category: Cardiology Source Type: news
PIONEER-HF: In-Hospital ARNI Shows Biomarker Benefit vs ACE-I PIONEER-HF: In-Hospital ARNI Shows Biomarker Benefit vs ACE-I
Prognostically powerful natriuretic peptides fell further in patients with stabilized, recently decompensated heart failure who were started in hospital on sacubitril/valsartan compared with enalapril.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 12, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
Hypertensive patients may benefit from folic acid supplements
Hypertensive adults with low platelet count who took a combined daily pill of both enalapril and folic acid saw a 73 percent reduction in their risk of first stroke compared to patients who took only enalapril daily, according to a study published in the Journal of the American College of Cardiology. (Source: World Pharma News)
Source: World Pharma News - May 8, 2018 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Folic Acid Cut Strokes in Hypertensive Patients on Enalapril
(MedPage Today) -- Lowered risk in those with low platelets and elevated homocysteine levels (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - May 7, 2018 Category: Cardiology Source Type: news
Enalapril Maleate Tablets (New - Discontinuation)
Drug Shortage (Source: FDA Drug Shortages)
Source: FDA Drug Shortages - November 15, 2017 Category: Drugs & Pharmacology Source Type: news
Vasotec (Enalapril) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 3, 2017 Category: Drugs & Pharmacology Source Type: news
Vaseretic (Enalapril Maleate-Hydrochlorothiazide Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 8, 2017 Category: Drugs & Pharmacology Source Type: news
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entresto® (sacubitril/valsartan) tablets improved glycemic control, as assessed by hemoglobin A1c (HbA1c) testing, compared to ACE-inhibitor enalapril[1]. (Source: World Pharma News)
Source: World Pharma News - March 20, 2017 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news
Know When Airway Discomfort is Indicative of Something Serious
Discussion
Coughing is a normal response that protects the airway. Typically, when an irritant enters the airway, the body responds by drawing in a quick breath and then closes the glottis as the air is forced out. This increases the pressure in the airways, which helps move the irritant out of the air passages. As the air is forced out past the closed glottis, the recognizable coughing sound is made. A cough that persists for several days or increases in its intensity and frequency can be a sign of a serious condition. (Source: JEMS Patient Care)
Source: JEMS Patient Care - February 26, 2017 Category: Emergency Medicine Authors: Dennis Edgerly, EMT-P Tags: Airway & Respiratory Columns Source Type: news
Enalapril Improves BP in T1DM Patients With Neuropathy Enalapril Improves BP in T1DM Patients With Neuropathy
Bedtime dosing of enalapril can increase blood pressure dipping in patients with type 1 diabetes and cardiovascular autonomic neuropathy (CAN), new research shows.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 28, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
In Heart Failure Patients, Severe Hyperkalemia Less Common with Sacubitril/Valsartan Than Enalapril (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Among patients with heart failure who are taking a mineralocorticoid receptor antagonist (MRA), the risk for severe hyperkalemia is lower … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - November 14, 2016 Category: Primary Care Source Type: news
